B. Halama

Response to “Can CYP3A Activity Be Evaluated for Drug Interaction Using a Nanogram Dose of Probe Drug?”: Evaluation of CYP3A Activity With Microdoses of Midazolam

W E Haefeli, W. Haefeli, G. Mikus, 2014, Clinical pharmacology and therapeutics.

A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions

W E Haefeli, W. Haefeli, G. Mikus, 2013, Clinical pharmacology and therapeutics.

Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry

Gerd Mikus, Walter E Haefeli, W. Haefeli, 2012, Analytical and Bioanalytical Chemistry.

A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions

N. Hohmann, B. Halama, Jürgen Burhenne, 2013, Clinical pharmacology and therapeutics.